| Subsequent Events [Text Block] |
| NOTE 6 - | SUBSEQUENT EVENTS | | A. | On July 13, 2017, the Company granted Common Stock of the Company and option to purchase shares of Common Stock of the Company to three officers of the Company and to one of its directors. Refer to note 5B2. | | B. | On July 26, 2017 the Company granted to its Chief Executive Officer shares of restricted common stock and an option to purchase shares of Common Stock. Refer to note 5B2. | | C. | On July 21, 2017, California Institute for Regenerative Medicine (CIRM) has awarded the Company a grant of $16 million to support the Company’s Phase 3 study. |
|